Cargando…
Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure
OBJECTIVE: To examine neurocognitive functioning of children exposed prenatally to carbamazepine, lamotrigine, levetiracetam or valproate monotherapy. METHODS: In a prospective observational study, children aged 6 or 7 years, identified from the European Registry of Antiepileptic Drugs and Pregnancy...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293688/ https://www.ncbi.nlm.nih.gov/pubmed/32112258 http://dx.doi.org/10.1007/s00415-020-09764-w |
_version_ | 1783546343055163392 |
---|---|
author | Huber-Mollema, Yfke van Iterson, Loretta Oort, Frans J. Lindhout, Dick Rodenburg, Roos |
author_facet | Huber-Mollema, Yfke van Iterson, Loretta Oort, Frans J. Lindhout, Dick Rodenburg, Roos |
author_sort | Huber-Mollema, Yfke |
collection | PubMed |
description | OBJECTIVE: To examine neurocognitive functioning of children exposed prenatally to carbamazepine, lamotrigine, levetiracetam or valproate monotherapy. METHODS: In a prospective observational study, children aged 6 or 7 years, identified from the European Registry of Antiepileptic Drugs and Pregnancy database in The Netherlands, were assessed using the Wechsler Intelligence Scale for Children and the developmental neuropsychological assessment. Maternal IQ was measured using Wechsler Adult Intelligence Scale. Assessors were blinded to drug exposures. RESULTS: One hundred and sixty-one children (one set of twins and 21 sibling pairs) of 139 mothers were included. As a group, children achieved average scores on neurocognitive outcomes. Children exposed to valproate (n = 22) performed lower on all six neurocognitive domains, especially language, than those exposed to carbamazepine (n = 32), lamotrigine (n = 82) or levetiracetam (n = 25). After controlling for maternal IQ and drug dose, the verbal IQ of valproate-exposed children was on average 9.1 points lower than those exposed to carbamazepine (95% confidence interval [CI] 1.3–17.0; p = 0.023), 10.3 lower than lamotrigine-exposed children (CI 3.4–17.3; p = 0.004) and 13.4 lower than levetiracetam-exposed children (CI 5.2–21.6; p = 0.002). No significant dose–effect was found. Virtually no significant differences were found between lamotrigine and levetiracetam or lamotrigine and carbamazepine exposed children. CONCLUSIONS: Consistent with previous research, valproate-exposed children experienced more problems compared to three other common antiepileptic drugs, while children exposed to lamotrigine, carbamazepine or levetiracetam revealed little to no problems. This illustrates the need for systematic follow-up of prenatally exposed children, to support pre-pregnancy counseling and treatment decisions in women of reproductive age. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00415-020-09764-w) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7293688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-72936882020-06-16 Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure Huber-Mollema, Yfke van Iterson, Loretta Oort, Frans J. Lindhout, Dick Rodenburg, Roos J Neurol Original Communication OBJECTIVE: To examine neurocognitive functioning of children exposed prenatally to carbamazepine, lamotrigine, levetiracetam or valproate monotherapy. METHODS: In a prospective observational study, children aged 6 or 7 years, identified from the European Registry of Antiepileptic Drugs and Pregnancy database in The Netherlands, were assessed using the Wechsler Intelligence Scale for Children and the developmental neuropsychological assessment. Maternal IQ was measured using Wechsler Adult Intelligence Scale. Assessors were blinded to drug exposures. RESULTS: One hundred and sixty-one children (one set of twins and 21 sibling pairs) of 139 mothers were included. As a group, children achieved average scores on neurocognitive outcomes. Children exposed to valproate (n = 22) performed lower on all six neurocognitive domains, especially language, than those exposed to carbamazepine (n = 32), lamotrigine (n = 82) or levetiracetam (n = 25). After controlling for maternal IQ and drug dose, the verbal IQ of valproate-exposed children was on average 9.1 points lower than those exposed to carbamazepine (95% confidence interval [CI] 1.3–17.0; p = 0.023), 10.3 lower than lamotrigine-exposed children (CI 3.4–17.3; p = 0.004) and 13.4 lower than levetiracetam-exposed children (CI 5.2–21.6; p = 0.002). No significant dose–effect was found. Virtually no significant differences were found between lamotrigine and levetiracetam or lamotrigine and carbamazepine exposed children. CONCLUSIONS: Consistent with previous research, valproate-exposed children experienced more problems compared to three other common antiepileptic drugs, while children exposed to lamotrigine, carbamazepine or levetiracetam revealed little to no problems. This illustrates the need for systematic follow-up of prenatally exposed children, to support pre-pregnancy counseling and treatment decisions in women of reproductive age. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00415-020-09764-w) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-02-28 2020 /pmc/articles/PMC7293688/ /pubmed/32112258 http://dx.doi.org/10.1007/s00415-020-09764-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Communication Huber-Mollema, Yfke van Iterson, Loretta Oort, Frans J. Lindhout, Dick Rodenburg, Roos Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure |
title | Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure |
title_full | Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure |
title_fullStr | Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure |
title_full_unstemmed | Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure |
title_short | Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure |
title_sort | neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293688/ https://www.ncbi.nlm.nih.gov/pubmed/32112258 http://dx.doi.org/10.1007/s00415-020-09764-w |
work_keys_str_mv | AT hubermollemayfke neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure AT vanitersonloretta neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure AT oortfransj neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure AT lindhoutdick neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure AT rodenburgroos neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure |